And I think one of the things that perhaps was somewhat surprising in the data we saw at ASCO with the high rate of discontinuations for toxicity of Kisqali, especially with many patients still on therapy.

Source: https://seekingalpha.com/article/4625481-eli-lilly-and-co-lly-q2-2023-earnings-call-transcript?source=feed_all_articles

In another update, Affimed revealed its plans to debut initial data from two expansion cohorts of the AFM24 monotherapy study at the upcoming ASCO meeting.

Source: https://seekingalpha.com/article/4609244-affimeds-q1-2023-analysis-financial-and-regulatory-challenges-persist?source=feed_all_articles

Is that something you do after the ASCO update, or--?

Source: https://seekingalpha.com/article/4585318-autolus-therapeutics-autl-q4-2022-earnings-call-transcript?source=feed_all_articles

So at ASCO, we should have data from all 150 patients who are enrolled.

Source: https://seekingalpha.com/article/4587681-gilead-sciences-inc-gild-presents-barclays-2023-global-healthcare-conference-transcript?source=feed_all_articles